--- title: "Twist Bioscience (NASDAQ:TWST) Shares Down 4.4% on Insider Selling" description: "Twist Bioscience (NASDAQ:TWST) shares fell 4.4% to $29.82 amid insider selling, with CFO Adam Laponis selling 2,517 shares at $32.92 and 3,000 shares at $31.15. Analysts have downgraded the stock, wit" type: "news" locale: "en" url: "https://longbridge.com/en/news/260924263.md" published_at: "2025-10-13T16:28:33.000Z" --- # Twist Bioscience (NASDAQ:TWST) Shares Down 4.4% on Insider Selling > Twist Bioscience (NASDAQ:TWST) shares fell 4.4% to $29.82 amid insider selling, with CFO Adam Laponis selling 2,517 shares at $32.92 and 3,000 shares at $31.15. Analysts have downgraded the stock, with Evercore ISI lowering its price target from $46 to $42. The stock has a market cap of $1.80 billion and a negative EPS of -$0.47. Institutional investors have increased their stakes, with UBS AM growing its position by 186.1%. Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report)'s stock price traded down 4.4% during mid-day trading on Monday following insider selling activity. The company traded as low as $29.89 and last traded at $29.82. 511,249 shares traded hands during mid-day trading, a decline of 60% from the average session volume of 1,276,625 shares. The stock had previously closed at $31.19. Get **Twist Bioscience** alerts: Specifically, CFO Adam Laponis sold 2,517 shares of the stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $32.92, for a total value of $82,859.64. Following the completion of the transaction, the chief financial officer directly owned 91,525 shares of the company's stock, valued at approximately $3,013,003. This trade represents a 2.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Adam Laponis sold 3,000 shares of the stock in a transaction dated Wednesday, October 8th. The shares were sold at an average price of $31.15, for a total transaction of $93,450.00. Following the completion of the transaction, the chief financial officer directly owned 94,042 shares of the company's stock, valued at approximately $2,929,408.30. This trade represents a 3.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. In other Twist Bioscience news, insider Dennis Cho sold 3,876 shares of the stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $32.19, for a total value of $124,768.44. Following the completion of the transaction, the insider directly owned 98,710 shares of the company's stock, valued at approximately $3,177,474.90. This trade represents a 3.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. ## Analyst Upgrades and Downgrades TWST has been the topic of several research reports. Evercore ISI lowered their price target on shares of Twist Bioscience from $46.00 to $42.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 7th. Weiss Ratings restated a "sell (d-)" rating on shares of Twist Bioscience in a research report on Wednesday, October 8th. Barclays decreased their target price on shares of Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating on the stock in a research report on Thursday, October 2nd. Finally, Cowen restated a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $48.50. **Get Our Latest Research Report on Twist Bioscience** ## Twist Bioscience Price Performance The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of -20.56 and a beta of 2.38. The business's 50 day simple moving average is $27.63 and its 200-day simple moving average is $32.53. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The business had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Research analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current year. ## Institutional Inflows and Outflows Institutional investors have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Twist Bioscience by 186.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock worth $95,883,000 after acquiring an additional 1,588,587 shares in the last quarter. EdgePoint Investment Group Inc. lifted its stake in shares of Twist Bioscience by 114.3% in the second quarter. EdgePoint Investment Group Inc. now owns 2,385,942 shares of the company's stock worth $87,779,000 after buying an additional 1,272,732 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Twist Bioscience in the first quarter worth $31,960,000. ARK Investment Management LLC raised its stake in Twist Bioscience by 11.5% during the 1st quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock valued at $245,045,000 after purchasing an additional 645,730 shares during the last quarter. Finally, Balyasny Asset Management L.P. raised its stake in Twist Bioscience by 934.0% during the 2nd quarter. Balyasny Asset Management L.P. now owns 628,241 shares of the company's stock valued at $23,113,000 after purchasing an additional 567,481 shares during the last quarter. ## About Twist Bioscience (Get Free Report) Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. ## See Also - Five stocks we like better than Twist Bioscience - Manufacturing Stocks Investing - 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk - Insider Trades May Not Tell You What You Think - Applied Digital’s Shorts Got Squeezed—Now What? - The 3 Best Fintech Stocks to Buy Now - Levi Strauss Stock Set to Reach New Highs in 2026 *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Twist Bioscience Right Now? Before you consider Twist Bioscience, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list. While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [TWST.US - Twist Bioscience](https://longbridge.com/en/quote/TWST.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Twist Bioscience｜8-K：2026 财年 Q1 营收 1.04 亿美元超过预期 | | [Link](https://longbridge.com/en/news/274512877.md) | | Twist Bioscience｜8-K：2026 财年 Q1 营收 1.04 亿美元超过预期 | | [Link](https://longbridge.com/en/news/272275744.md) | | 华尔街大佬 Tepper 押注 AI：美光持仓激增 200%，新买韩国 ETF | 对冲基金大佬 Tepper 去年四季度精准狙击 AI 芯片赛道，豪掷逾 6 亿美元重仓美光科技和韩国芯片 ETF，今年已斩获约 30% 回报。全球内存短缺叠加 AI 算力狂潮，其芯片押注与软件股暴跌形成冰火两重天。 | [Link](https://longbridge.com/en/news/276213747.md) | | 达利欧家办重仓黄金！彻底退出桥水后首曝美股持仓，规模升至 5 亿美元 | 达利欧家族办公室自疫情以来首次披露美国股票投资情况。截至去年年底，其在美股市场持仓约 5.03 亿美元，较 2021 年初增长约三分之一。其中超过四分之三资金配置在黄金 ETF，其余分散布局美债及标普 500 指数等资产。分析称，这一举动显 | [Link](https://longbridge.com/en/news/276472669.md) | | 一文读懂 2026 年至今的全球市场：什么在涨？美股为何不行？这种趋势会持续吗？ | 高盛报告揭示 2026 年市场新风向：周期性资产上涨仍有空间；但 AI 等热门主题估值过高，高波动或成为未来常态；美元将持续疲软；建议警惕高估值板块，分散股票持仓、保持健康的非美敞口（包括新兴市场），以及较长期限指数波动率的做多头寸。 | [Link](https://longbridge.com/en/news/276406606.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.